Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.
Summary
This phase 3 study evaluated the efficacy and safety of daraxonrasib, a multiselective RAS(ON) inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Patients were randomized to receive either daraxonrasib or investigator's choice chemotherapy. Results demonstrated significantly longer overall survival and progression-free survival with daraxonrasib compared to chemotherapy, both in the RAS G12 mutated population and the overall population. Daraxonrasib also showed a favorable safety profile, with a significantly lower rate of treatment discontinuation due to adverse events compared to chemotherapy.
Analysis
This phase 3 study is highly clinically relevant, demonstrating a significant benefit of daraxonrasib in previously treated metastatic PDAC patients, a population with limited therapeutic options. Daraxonrasib doubled median overall survival (13.2 months vs 6.6-6.7 months) and median progression-free survival (7.2-7.3 months vs 3.5-3.6 months) compared to chemotherapy, with a hazard ratio of 0.40 for overall survival and 0.45-0.49 for progression-free survival (p<0.001 for all comparisons). These robust results suggest that daraxonrasib could become a new standard of care. The clinical impact is potentially immediate (1-3 years) if the drug is approved, justifying a practice change for previously treated metastatic PDAC patients, especially those with RAS G12, G13, or Q61 mutations. Daraxonrasib acts as a predictive biomarker for patients with RAS mutations, but its efficacy is also observed in the overall population, which is an advantage.